Literature DB >> 25912489

Incidence and patterns of late recurrences in colon cancer patients.

Anne-Marie Bouvier1, Guy Launoy2, Véronique Bouvier2, Fabien Rollot1, Sylvain Manfredi3, Jean Faivre1, Vanessa Cottet1, Valérie Jooste1.   

Abstract

Long-term recurrences of colon cancer raised questions about the possible benefit of prolonging the recommended active 5-year surveillance. The aim of this study was to determine, for the first time, the incidence and patterns of late 10-year recurrence following curative resection of colon cancer. Data were obtained from two French digestive cancer registries. A total of 3,622 patients under 85 years resected for cure for colon cancer diagnosed between 1985 and 2000 were included. Information regarding recurrences was actively collected. Cumulative failure rates at 10 years were estimated using Kaplan-Meier estimates corrected by cause-specific hazards, and multivariable analysis was performed using a model for the subdistribution of a competing risk proposed by Fine and Gray. The overall cumulative recurrence rate between 5 and 10 years after initial surgery was 2.9% for local recurrence and 4.3% for distant metastasis. Among men with no recurrence 5 years after diagnosis of colon cancer, 1 in 12 developed a recurrence between 5 and 10 years, and the corresponding cumulative rate was 7.8%. The frequency was 1 in 19 for women, corresponding to a cumulative rate of 5.2%. In the multivariate analysis, non-emergency diagnostic feature, female sex and age under 75 were associated with a lower risk of recurrence. Stage at diagnosis was not a predictor of late recurrence. Late recurrence after colon cancer resection with curative intent can occur. A regular clinical follow-up is necessary to detect early signs of possible recurrence.
© 2015 UICC.

Entities:  

Keywords:  cancer registry; colon cancer; distant metastases; local recurrence; long-term recurrence

Mesh:

Year:  2015        PMID: 25912489     DOI: 10.1002/ijc.29578

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Do Stage I Colorectal Cancers with Lymphatic Invasion Require a Different Postoperative Approach?

Authors:  Lieve G J Leijssen; Anne M Dinaux; Hiroko Kinutake; Liliana G Bordeianou; David L Berger
Journal:  J Gastrointest Surg       Date:  2018-12-03       Impact factor: 3.452

2.  Rectal Cancer Surveillance-Recurrence Patterns and Survival Outcomes from a Cohort Followed up Beyond 10 Years.

Authors:  Winson Jianhong Tan; Hiang Jin Tan; Sreemanee Raaj Dorajoo; Fung Joon Foo; Choong Leong Tang; Min Hoe Chew
Journal:  J Gastrointest Cancer       Date:  2018-12

3.  Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer.

Authors:  Jonah Popp; David S Weinberg; Eva Enns; John A Nyman; J Robert Beck; Karen M Kuntz
Journal:  Value Health       Date:  2021-10-13       Impact factor: 5.101

4.  Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review.

Authors:  Paul L Feingold; Nicholas D Klemen; Mei Li M Kwong; Barry Hashimoto; Udo Rudloff
Journal:  Int J Hyperthermia       Date:  2017-12-07       Impact factor: 3.914

5.  Defining early recurrence in patients with resected primary colorectal carcinoma and its respective risk factors.

Authors:  Felix Wiesmueller; Rolf Schuetz; Melanie Langheinrich; Maximilian Brunner; Georg F Weber; Robert Grützmann; Susanne Merkel; Christian Krautz
Journal:  Int J Colorectal Dis       Date:  2021-01-15       Impact factor: 2.571

6.  Synchronous polypectomy during endoscopic diagnosis of colorectal cancer - is the risk of tumour implantation at the polypectomy site significant?

Authors:  W J Tan; N Zp Ng; Y D Chen; Y H M Chee; F J Foo; C L Tang; M H Chew
Journal:  BMC Gastroenterol       Date:  2018-08-29       Impact factor: 3.067

7.  Aberrant Expression of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer and Their Association with Cancer Progression and Prognosis.

Authors:  Musa Yaghoubizadeh; Leila Pishkar; Gholam Basati
Journal:  Gastrointest Tumors       Date:  2019-11-01

8.  Detection of metastatic cancer cells in mesentery of colorectal cancer patients.

Authors:  Xue-Lai Luo; Da-Xing Xie; Jian-Xin Wu; An-Ding Wu; Zong-Qing Ge; Hai-Jie Li; Jun-Bo Hu; Zhi-Xin Cao; Jian-Ping Gong
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

9.  ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.

Authors:  Z Kozovska; A Patsalias; V Bajzik; E Durinikova; L Demkova; S Jargasova; B Smolkova; J Plava; L Kucerova; M Matuskova
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.638

10.  FBX8 promotes metastatic dormancy of colorectal cancer in liver.

Authors:  Xiaohui Zhu; Feifei Wang; Xuehui Wu; Zhou Li; Zhizhi Wang; Xiaoli Ren; Yangshu Zhou; Fuyao Song; Yunshi Liang; Zhicheng Zeng; Wangjun Liao; Yanqing Ding; Wenting Liao; Li Liang
Journal:  Cell Death Dis       Date:  2020-08-14       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.